Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class III · Low risk

Advair HFA

Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.

Terminated Stability / shelf life GlaxoSmithKline, LLC. NDC 0173-0715-22 D-065-2013
Class III · Low risk

Advair HFA

Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.

Terminated Stability / shelf life GlaxoSmithKline, LLC. NDC 0173-0715-20 D-064-2013
Class III · Low risk

ESTEE LAUDER DayWear Sheer Tint Release

Failed Stability Specifications: The active sunscreen ingredient, avobenzone 3%, may not be stable over the shelf life, the sunscreen effectiveness may be less than labeled.

Terminated Stability / shelf life Estee Lauder Inc NDC 11559-008-01 D-151-2013
Class I · High risk

Ultimate Formula

Marketed Without An Approved NDA/ANDA: Products were found to contain undeclared sibutramine, the active ingredient in a previously approved FDA product indicated for weight loss but removed from the market for safety reasons, making these products unapproved new drugs.

Terminated Chemical / undeclared Zi Xiu Tang Success, LLC D-370-2014
Class I · High risk

Classic Zi Xiu Tang

Marketed Without An Approved NDA/ANDA: Products were found to contain undeclared sibutramine, the active ingredient in a previously approved FDA product indicated for weight loss but removed from the market for safety reasons, making these products unapproved new drugs.

Terminated Chemical / undeclared Zi Xiu Tang Success, LLC D-369-2014
Class II · Moderate risk

Necon 1/35-28

Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).

Terminated Cross-contamination Watson Laboratories Inc NDC 52544-552-28 D-017-2013
Class II · Moderate risk

Necon 10/11

Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).

Terminated Cross-contamination Watson Laboratories Inc NDC 52544-554-28 D-016-2013
Class II · Moderate risk

Zenchent (norethindrone and ethinyl estradiol)

Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).

Terminated Cross-contamination Watson Laboratories Inc NDC 52544-953-28 D-015-2013
Class II · Moderate risk

Lutera (levonorgestrel and ethinyl estradiol)

Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).

Terminated Cross-contamination Watson Laboratories Inc NDC 52544-949-28 D-014-2013
Class II · Moderate risk

Zovia (ethynodiol diacetate and ethinyl estradiol)

Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).

Terminated Cross-contamination Watson Laboratories Inc NDC 52544-383-28 D-013-2013
Class III · Low risk

AcneFree Acne Pore Cleanser

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the benzoyl peroxide active ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-049-2013
Class III · Low risk

AcneFree Severe Maximum Strength Acne Pore Cleanser

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the benzoyl peroxide active ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-048-2013
Class III · Low risk

AcneFree 3-in-1 Acne Night Repair Foam

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the salicylic acid ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-047-2013
Class III · Low risk

AcneFree Original Strength Terminator

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the benzoyl peroxide active ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-045-2013
Class III · Low risk

AcneFree Oil-Free Acne Cleanser

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the benzoyl peroxide active ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-044-2013
Class III · Low risk

AcneFree 24 Hour Clearing System containing 1-count 4 fl oz

Subpotent (Single Ingredient) Drug: This product was found to be subpotent for the benzoyl peroxide active ingredient. Additionally, this product is mislabeled because the label either omits or erroneously added inactive ingredients to the label.

Terminated Wrong potency / content Valeant Pharmaceuticals D-042-2013
Class II · Moderate risk

Perphenazine Tablets

Tablet Separation: Possibility of cracked or split coating on the tablets.

Terminated Failed specification Vintage Pharmaceuticals LLC DBA Qualitest Pharmaceuticals NDC 0603-5092-21 D-010-2013
Class II · Moderate risk

QUETIAPINE Fumarate Tablets 25mg 100 Tablets

Failed Dissolution Test Requirements: During analysis of long term stability studies at 3 months time point, an OOS was reported for Quetiapine Fumarate Tablets, 25 mg.

Terminated Dissolution failure American Health Packaging NDC 68084-530-01 D-802-2013
Class II · Moderate risk

Arranon (nelarabine)

Impurities/Degradation Products: Potential for drug related impurities to exceed the specification limits.

Terminated Impurity / degradation GlaxoSmithKline, LLC. NDC 0007-4401-06 D-068-2013

Recalls by year